4Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors(ovarian cancer)[J]. J Natl Cancer Inst, 2004, 96(6):487-488.
5Vergote I, Rustin GJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)gynecologic cancer intergroup [J]. J Natl Cancer Inst, 2000, 92(18): 1534-1535.
6Shapiro JD, Millward Mj, Rischin D, et al. Activity of gemeitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel[J].Gynecol Oncol, 1996, 63(1):89-93.
7Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines[J]. Mol Pharmacol, 2003, 63(4) : 862-869.
8Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase Ⅱ study of the Gynecologic Oncology Group[J]. Gynecol Oncol, 2006, 103(2):446-450.
9Bozas G, Bamias A, Kout Soukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma [J]. Gynecol Oncol, 2007, 104(3): 580-585.
10Tewari D, Monk B J, Hunter M, et al. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J]. Invest New Drugs, 2004, 22(4): 475-480.
1Donovan HS, Ward SE, Sereika SM, et al. Web -based symp- tom management for women with recurrent ovarian cancer:A pilot randomized controlled trial of the WRITE symptoms inter- vention [ J ]. Journal of Pain and Symptom Management, 2014, 47(2) :21.8 -230.
